{"log_id": 7168219514187276457, "direction": 0, "words_result_num": 28, "words_result": [{"probability": {"variance": 0, "average": 0.99947, "min": 0.999222}, "location": {"width": 32, "top": 271, "height": 24, "left": 364}, "words": "75"}, {"probability": {"variance": 0.000887, "average": 0.948995, "min": 0.919217}, "location": {"width": 20, "top": 356, "height": 21, "left": 370}, "words": "60"}, {"probability": {"variance": 0.024401, "average": 0.889362, "min": 0.668452}, "location": {"width": 68, "top": 434, "height": 27, "left": 327}, "words": "况45"}, {"probability": {"variance": 0.068997, "average": 0.811431, "min": 0.439957}, "location": {"width": 68, "top": 507, "height": 31, "left": 323}, "words": "30"}, {"probability": {"variance": 0.012841, "average": 0.910784, "min": 0.609779}, "location": {"width": 173, "top": 522, "height": 27, "left": 526}, "words": "0-氯沙坦钾50mg"}, {"probability": {"variance": 5.1e-05, "average": 0.994295, "min": 0.979337}, "location": {"width": 75, "top": 554, "height": 23, "left": 567}, "words": "(n=337"}, {"probability": {"variance": 0.000154, "average": 0.984898, "min": 0.972469}, "location": {"width": 31, "top": 594, "height": 23, "left": 362}, "words": "15"}, {"probability": {"variance": 0.003102, "average": 0.958352, "min": 0.812762}, "location": {"width": 151, "top": 597, "height": 26, "left": 561}, "words": "阿利沙坦酯2401"}, {"probability": {"variance": 0.00207, "average": 0.965567, "min": 0.866874}, "location": {"width": 75, "top": 630, "height": 21, "left": 566}, "words": "(n=344)"}, {"probability": {"variance": 0.000863, "average": 0.986741, "min": 0.90405}, "location": {"width": 364, "top": 700, "height": 31, "left": 383}, "words": "基线4周8周12周"}, {"probability": {"variance": 0.001272, "average": 0.989178, "min": 0.810932}, "location": {"width": 781, "top": 808, "height": 38, "left": 252}, "words": "图1.阿利沙坦酯与氯沙坦钾在临床对照试验中的结果比较。有效指"}, {"probability": {"variance": 0.003733, "average": 0.977173, "min": 0.605951}, "location": {"width": 780, "top": 854, "height": 38, "left": 252}, "words": " SBP/DBP<140mmHg85mmHg或SBP下降20mmHg和或DBP下降10mmHg。达标"}, {"probability": {"variance": 0.00417, "average": 0.901507, "min": 0.838156}, "location": {"width": 316, "top": 902, "height": 28, "left": 254}, "words": " :ESBP/DBP<140mmhg/90mmhg"}, {"probability": {"variance": 1e-06, "average": 0.998847, "min": 0.996766}, "location": {"width": 125, "top": 974, "height": 27, "left": 244}, "words": "【药理毒理】"}, {"probability": {"variance": 0, "average": 0.985527, "min": 0.985527}, "location": {"width": 23, "top": 1000, "height": 25, "left": 1105}, "words": "业"}, {"probability": {"variance": 2e-06, "average": 0.997913, "min": 0.99601}, "location": {"width": 92, "top": 1020, "height": 28, "left": 237}, "words": "作用机制"}, {"probability": {"variance": 0.011092, "average": 0.955132, "min": 0.564313}, "location": {"width": 758, "top": 1065, "height": 38, "left": 280}, "words": "血管紧张素ⅡI(AngIⅡI)是由血管紧张素I(AngI)经过血管紧张素转化"}, {"probability": {"variance": 0.003051, "average": 0.982659, "min": 0.74293}, "location": {"width": 802, "top": 1110, "height": 40, "left": 236}, "words": "酶(ACE,激肽酶Ⅱ)催化转化而成的,是肾素一血管紧张素系统(RAS)的"}, {"probability": {"variance": 0.000178, "average": 0.994846, "min": 0.920879}, "location": {"width": 804, "top": 1155, "height": 43, "left": 234}, "words": "关键性产物,在高血压的病理生理过程中起主要作用。AngⅡ受体有两种:1型"}, {"probability": {"variance": 0.000209, "average": 0.996314, "min": 0.90944}, "location": {"width": 789, "top": 1204, "height": 39, "left": 247}, "words": "(AT1)和2型(AT2)。在很多组织(如血管平滑肌、肾上腺、肾脏和心脏)中"}, {"probability": {"variance": 0.017372, "average": 0.960701, "min": 0.386696}, "location": {"width": 798, "top": 1251, "height": 40, "left": 239}, "words": "AnⅡI和AT1受体结合,引起几种重要的生物学作用,包括血管收缩、醛固酮"}, {"probability": {"variance": 6.4e-05, "average": 0.9963, "min": 0.955796}, "location": {"width": 802, "top": 1298, "height": 40, "left": 231}, "words": "释放、心脏收缩、钠重吸收和刺激平滑肌细胞增生等。AT2受体分布也较广"}, {"probability": {"variance": 7e-06, "average": 0.998124, "min": 0.990382}, "location": {"width": 538, "top": 1345, "height": 34, "left": 230}, "words": "泛,但它对于心血管系统功能稳态的作用尚不明确"}, {"probability": {"variance": 9e-06, "average": 0.998248, "min": 0.986381}, "location": {"width": 758, "top": 1391, "height": 39, "left": 276}, "words": "阿利沙坦酯经酯酶代谢产生与氯沙坦钾经肝脏代谢产生相同的活性代谢产"}, {"probability": {"variance": 0.000352, "average": 0.990838, "min": 0.913929}, "location": {"width": 806, "top": 1438, "height": 40, "left": 230}, "words": "物E3174(单次口服阿利沙坦酯240mg或氯沙坦钾100mg,生成的E3174的"}, {"probability": {"variance": 0.009204, "average": 0.963256, "min": 0.397507}, "location": {"width": 804, "top": 1486, "height": 38, "left": 231}, "words": " Auclast分别为4.43hrmg/L和4.76hr*mgL)。E3174能与AT1受体选择性结"}, {"probability": {"variance": 0.000176, "average": 0.996063, "min": 0.922504}, "location": {"width": 788, "top": 1533, "height": 39, "left": 230}, "words": "合,阻断任何来源或任何途径合成的血管紧张素Ⅱ所产生的相应的生理作用"}, {"probability": {"variance": 0.001305, "average": 0.945768, "min": 0.90476}, "location": {"width": 38, "top": 1598, "height": 20, "left": 625}, "words": "/11"}], "language": 3}